Early adopters come together to dialog with the makers of the Quell
WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (Nasdaq: NURO) held its first Quell®
Wearable Pain Relief Technology™ user event last Thursday, April 27. As
a customer-focused company, NeuroMetrix frequently looks to its users to
inform product updates and innovation.
NeuroMetrix welcomed a group of 30 Quell users to its Waltham
headquarters to "meet the makers," learn about upcoming Quell product
features, share their stories, and give feedback on the product. Quell
users learned about product development directly from Shai N. Gozani,
M.D., Ph.D., President and CEO at NeuroMetrix, and connected with peers
and NeuroMetrix's customer care, engineering, and marketing teams.
"We know that Governor Baker's goal is to establish Massachusetts as a
digital health hub and we are proud to contribute to that mission as a
Massachusetts-based digital health company," said Frank McGillin, Senior
Vice President and Chief Commercial Officer at NeuroMetrix. "Many of
those living with chronic pain in the Commonwealth have been reliant on
medication to manage their day-to-day pain. Hearing that Quell has
enabled many of the event's attendees to reduce or eliminate their use
of opioids was a rewarding experience. We look forward to hosting more
of these events in the future."
Attendees had the opportunity to share their experiences and discuss how
Quell has changed their approach to pain management. "I did not know
what it was like to live life without pain, until I got my Quell," said
one attendee. Another Quell user stated, "Quell has returned my freedom
to choose what I want to do daily, not what my pain will let me do
today. I have my life back again!"
While Quell provides an opportunity to reduce drug reliance, the reality
is that many chronic pain sufferers will require some degree of
continued usage of medications to deal with their pain. NeuroMetrix
believes a "treatment toolbox" approach that looks to supplement pain
medications with technology and other alternatives may be effective in
"There is no one-size-fits-all approach to treating chronic pain. Our
goal is to provide a drug free treatment option to enhance the quality
of life for those living with chronic pain," said Dr. Gozani. "As a
consumer health company, engaging our users is critical to achieving
this goal. We were impressed by the response we received and will be
applying this feedback to continue improving our product."
Quell is designed for millions of people
suffering from chronic pain. The advanced wearable device is lightweight
and can be worn during the day while active, and at night while
sleeping. It has been cleared by the FDA for treatment of chronic pain
without a prescription. In a recent study, 81% of Quell users reported
an improvement in their chronic pain. Quell users can personalize and
manage therapy discreetly via the Quell Relief app. Quell also offers
advanced health tracking relevant to chronic pain sufferers including
pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW
(South by Southwest) Innovation Award for Best Wearable Technology.
Quell is available at select healthcare professionals and retailers.
for more information.
NeuroMetrix is a commercial stage,
innovation driven healthcare company combining bioelectrical and digital
medicine to address chronic health conditions including chronic pain,
sleep disorders, and diabetes. The company's lead product is Quell, an
over-the-counter wearable therapeutic device for chronic pain. Quell is
integrated into a digital health platform that helps patients optimize
their therapy and decrease the impact of chronic pain on their quality
of life. The company also markets DPNCheck®, a rapid
point-of-care test for diabetic neuropathy, which is the most common
long-term complication of Type 2 diabetes. The company maintains an
active research effort and has several pipeline programs. The company is
located in Waltham, Massachusetts and was founded as a spinoff from the
Harvard-MIT Division of Health Sciences and Technology in 1996. For more
information, please visit NeuroMetrix.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170505005689/en/
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
Source: NeuroMetrix, Inc.
News Provided by Acquire Media